聚焦医药违法广告，市场监管部门推出治理“组合拳”

Core Viewpoint - The recent announcement by the State Administration for Market Regulation (SAMR) regarding typical cases of illegal advertising highlights the ongoing issues of false advertising and exaggerated claims in the medical and pharmaceutical sectors, necessitating stricter regulatory measures to protect consumer rights and public health [1][3][5]. Regulatory Actions - In April 2023, SAMR issued a notice focusing on five key areas, including medical, pharmaceutical, health food, special medical purpose formula food, and medical device advertising, to enhance market order and consumer protection [1][5]. - The release of the "Medical Advertising Regulatory Work Guidelines" in May 2023 marks a new phase in the regulation of medical advertising, providing clear legal boundaries and institutional support for patient rights and market order [2][6]. Case Examples - Among the ten typical cases of illegal advertising published, six involved the pharmaceutical sector, including a case where a company was fined 194,000 yuan for advertising unapproved medical devices [3][4]. - Other cases included misleading advertisements for medical services and products claiming disease prevention or treatment capabilities, resulting in fines totaling 1.4 million yuan across various cases [3][4]. Enforcement Statistics - As of April 2023, nationwide efforts have led to the investigation of 11,459 illegal advertising cases, with fines totaling approximately 88.31 million yuan [5][6]. - Specific regions, such as Anhui, reported 1,458 leads on illegal medical advertising and 452 cases of violations, demonstrating the effectiveness of local regulatory actions [5]. Future Directions - Experts suggest enhancing the regulatory framework by refining advertising review standards and establishing comprehensive monitoring mechanisms [7]. - The introduction of technology-driven solutions, such as an intelligent monitoring system for medical advertisements, is recommended to improve compliance and enforcement [7].